ArticleMedicine2026
Mendelian randomization followed by single-cell RNA sequencing exploration identifies effector memory CD4+ T cells as a risk factor for myasthenia gravis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is an autoimmune neuromuscular junction disease classified as early onset MG (EOMG), which typically occurs before the age of 50 years, and late-onset MG (LOMG), which occurs after the age of 50 years. The contribution of different immune cell subsets to MG pathogenesis is not fully understood. To address this, we conducted 2-sample Mendelian randomization (MR) analyses incorporating 731 peripheral immunophenotypes associated with MG. To further explore cellular mechanisms, we analyzed an existing single-cell RNA sequencing (scRNA-seq) dataset derived from the peripheral blood of patients with MG during and after the myasthenic crisis phase. In MR analyses, IVW results suggested that 42 immunophenotypes were risk or protective factors for LOMG, whereas 28 immunophenotypes were involved in EOMG. Comprehensive sensitivity analyses confirmed the absence of heterogeneity and horizontal pleiotropy. Among these, the proportion of effector memory CD4 + T cells emerged as the most significant factor associated with an increased risk of LOMG. Single-cell analyses revealed an expansion of these cells in patients with LOMG during the myasthenic crisis stage compared with the stable stage, with functional annotations showing strong similarities to activated CD4 + T cells treated with TGF-β and IL-4. This study identified effector memory CD4 + T cells as a significant risk factor for LOMG through MR analyses and further explored an existing scRNA-seq dataset. The role of effector memory CD4 + T cells, potentially mediated by TGF-β and IL-4, in LOMG pathogenesis and disease exacerbation, highlighting the need for further functional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.